Sanofi's diabetes drug Lyxumia approved in Europe (Reuters, 4 February 2013)

Sanofi's Lyxumia (lixisenatide) has been granted marketing authorisation in Europe for the treatment of type 2 diabetes in combination with other drugs or insulin.

Full article